China Pharma Holdings (CPHI) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$3.9M

Revenue (quarter)

$948,340.00

Revenue growth (year over year)

−7.55%

Gross profit (trailing twelve months)

$460,174.00

Gross margin

11.76%

Net income (trailing twelve months)

−$4.5M

Net income (quarter)

−$1.5M

Net income growth (year over year)

−175.97%

Net margin

−114.33%

Return on equity

−20.99%

EPS (trailing twelve months)

−$0.42

Book value per share

$0.89

P/E (trailing twelve months)

—

Price to book

0.89

Debt to assets

19.08%

Payout ratio

—

Dividend yield

—

Company profile

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

• Is China Pharma Holdings (CPHI) profitable?

  No. China Pharma Holdings reported a net loss of $4.5M over the trailing twelve months.

• How much revenue does China Pharma Holdings (CPHI) make?

  China Pharma Holdings generated $3.9M in revenue over the trailing twelve months, down 7.55% year over year.

• How do I buy stock in China Pharma Holdings (CPHI)?

  CPHI trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.